Recombinant Canine GM-CSF Protein

Catalog #: 1546-GM
11 Citations Datasheet / COA / SDS

Carrier Free

Catalog #	Availability	Size / Price	Qty
1546-GM-025/CF

With Carrier

Catalog #	Availability	Size / Price	Qty
1546-GM-025

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Citations (11)

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Canine GM-CSF Protein Summary

Product Specifications

Purity

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

Activity

Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The ED₅₀ for this effect is 1-4 ng/mL.

Source

E. coli-derived canine GM-CSF protein
Ala18-Lys144

Accession #

P48749.1

N-terminal Sequence
Analysis

Ala18

Predicted Molecular Mass

14.2 kDa

Product Datasheets

1546-GM (with carrier)

Product Datasheet

COA

SDS

1546-GM/CF (carrier free)

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1546-GM

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

1546-GM/CF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: GM-CSF

GM-CSF was initially characterized as a factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3 - 5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled alpha -helices (8 - 10). Mature canine GM-CSF shares 49% - 57% amino acid sequence identity with mouse and rat GM-CSF and 69% - 72% with feline, human, and porcine GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R alpha /CD116 and the signal transducing common beta chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (11, 12). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R alpha (13). The activity of GM-CSF is species specific between human and mouse, although human GM-CSF is active on canine cells (14, 15).

References

Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509.
Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163.
Cao, Y. (2007) J. Clin. Invest. 117:2362.
Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.
Heuser, M. et al. (2007) Semin. Hematol. 44:148.
Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321.
Kaushansky, K. et al. (1992) Biochemistry 31:1881.
Diederichs, K. et al. (1991) Science 254:1779.
Nash, R.A. et al. (1991) Blood 78:930.
Onetto-Pothier, N. et al. (1990) Blood 75:59.
Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. USA 87:9655.
Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.
Shanafelt, A.B. et al. (1991) J. Biol. Chem. 266:13804.
Hogge, G.S. et al. (1990) Cancer Gene Ther. 6:26.

Long Name

Granulocyte Macrophage Growth Factor

Entrez Gene IDs

1437 (Human); 12981 (Mouse); 116630 (Rat); 397208 (Porcine); 403923 (Canine); 493805 (Feline)

Alternate Names

colony stimulating factor 2 (granulocyte-macrophage); Colony-stimulating factor; CSF; CSF2; CSF-2; GMCSF; GM-CSF; GMCSFgranulocyte-macrophage colony-stimulating factor; granulocyte-macrophage colony stimulating factor; MGC131935; MGC138897; Molgramostim; molgramostin; Sargramostim

Related Research Areas

Citations for Recombinant Canine GM-CSF Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

11 Citations: Showing 1 - 10
Filter your results:

Filter by:

Characterization of polarization states of canine monocyte derived macrophages
Authors: Lyu, Q;Veldhuizen, EJA;Ludwig, IS;Rutten, VPMG;van Eden, W;Sijts, AJAM;Broere, F;
PloS one
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
Evaluation of the Efficacy of the Brucella canis RM6/66 deltavjbR Vaccine Candidate for Protection against B. canis Infection in Mice
Authors: LW Stranahan, SP Chaki, DG Garcia-Gon, OH Khalaf, AM Arenas-Gam
mSphere, 2020-05-20;5(3):.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
Authors: V Konduri, MM Halpert, YC Baig, R Coronado, JR Rodgers, JM Levitt, B Cerroni, S Piscoya, N Wilson, L DiBernardi, Z Omarbekov, L Seelhoff, V Ravi, L Douglass, WK Decker
Cancer Gene Ther., 2019-01-23;0(0):.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy
Authors: AJ Hernández-, MA Franco-Mol, EE Coronado-C, P Zapata-Ben, EM Gamboa, Y Ramos-Zaya, SE Santana-Kr, C Rodríguez-
Res. Vet. Sci., 2018-10-05;121(0):23-30.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages in vitro
Authors: F Heinrich, A Lehmbecker, BB Raddatz, K Kegler, A Tipold, VM Stein, A Kalkuhl, U Deschl, W Baumgärtne, R Ulrich, I Spitzbarth
PLoS ONE, 2017-08-17;12(8):e0183572.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A
PLoS ONE, 2016-11-11;11(11):e0165477.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.
Authors: Bauer TR, Olson EM, Huo Y
Gene Ther., 2011-01-13;18(6):553-9.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.
Authors: Xiong W, Candolfi M, Liu C
PLoS ONE, 2010-06-11;5(6):e11074.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model.
Authors: Lange S, Altmann S, Brandt B, Adam C, Riebau F, Vogel H, Weirich V, Hilgendorf I, Storb R, Freund M, Junghanss C
Exp. Hematol., 2009-01-01;37(1):143-50.
Species: Canine
Sample Types: Whole Cells
Applications: Bioassay
Preventive and therapeutic effects of gene therapy using silica nanoparticles-binding of GM-CSF gene on white blood cell production in dogs with leukopenia.
Authors: Choi EW, Koo HC, Shin IS, Chae YJ, Lee JH, Han SM, Lee SJ, Bhang DH, Park YH, Lee CW, Youn HY
Exp. Hematol., 2008-06-11;36(9):1091-7.
Species: Canine
Sample Types: N/A, Serum
Applications: ELISA (Capture), ELISA (Standard)

Effects of GM-CSF gene transfer using silica-nanoparticles as a vehicle on white blood cell production in dogs.
Authors: Choi EW, Shin IS, Chae YJ, Koo HC, Lee JH, Chung TH, Park YH, Kim DY, Hwang CY, Lee CW, Youn HY
Exp. Hematol., 2008-04-02;36(7):807-15.
Applications: ELISA (Standard)